Pfizer has announced additional results from the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA) evaluating the efficacy of Prevnar 13 (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) in preventing a first episode of vaccine-type community-acquired pneumonia (CAP) in adults aged ≥65 years. CAPiTA is the first trial to demonstrate a considerable reduction in vaccine-type pneumococcal and non-bacteremic/non-invasive vaccine-type pneumococcal CAP in adults.
In this double-blind, randomized, placebo-controlled study of approximately 85,000 adults aged ≥65 years, there were 45.56% fewer first episodes of vaccine-type CAP among Prevenar 13-vaccinated patients compared to those receiving placebo (P=0.0006). For the secondary objectives, those receiving Prevenar 13 had 45% fewer first episodes of non-bacteremic/non-invasive vaccine-type CAP (P=0.0067) and 75% fewer first episodes of vaccine-type IPD (P=0.0005) compared to the placebo group. Data also showed that patients receiving Prevenar 13 had reductions in vaccine-type and non-bacteremic/non-invasive vaccine-type CAP, as well as vaccine-type IPD for up to four years post-vaccination.
Prevnar 13 is already indicated for the immunization of adults aged >50 years for the prevention of pneumococcal pneumonia and invasive disease caused by 13 Streptococcus pneumoniae strains; for the prevention of invasive disease caused by the 13 vaccine strains in children 6 weeks–17 years of age; and for the prevention of otitis media caused by 7 of the 13 strains in children 6 weeks–5 years of age.
For more information, call (800) 505-4426 or visit Prevnar13.com.